Inactivation of the Hepatic Cytochrome P450 System by Conditional Deletion of Hepatic Cytochrome P450 Reductase
Open accessThe DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
Cytochrome P450 (CYP) monooxygenases catalyze the oxidation of a large number of endogenous compounds and the majority of ingested environmental chemicals, leading to their elimination and often to their metabolic activation to toxic products. This enzyme system therefore provides our primary defense against xenobiotics and is a major determinant in the therapeutic efficacy of pharmacological agents. To evaluate the importance of hepatic P450s in normal homeostasis, drug pharmacology, and chemical toxicity, we have conditionally deleted the essential electron transfer protein, NADH:ferrihemoprotein reductase (EC, cytochrome P450 reductase, CPR) in the liver, resulting in essentially complete ablation of hepatic microsomal P450 activity. Hepatic CPR-null mice could no longer break down cholesterol because of their inability to produce bile acids, and whereas hepatic lipid levels were significantly increased, circulating levels of cholesterol and triglycerides were severely reduced. Loss of hepatic P450 activity resulted in a 5-fold increase in P450 protein, indicating the existence of a negative feedback pathway regulating P450 expression. Profound changes in the in vivo metabolism of pentobarbital and acetaminophen indicated that extrahepatic metabolism does not play a major role in the disposition of these compounds. Hepatic CPR-null mice developed normally and were able to breed, indicating that hepatic microsomal P450-mediated steroid hormone metabolism is not essential for fertility, demonstrating that a major evolutionary role for hepatic P450s is to protect mammals from their environment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, these mice had hepatomegaly, accumulated hepatic lipids, and had a 99% decrease in bile acids, 65% decrease in serum cholesterol, and 50% decrease in serum triglycerides.”
From The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders (2011) · cites this paper as [312]
In the citing paper
“By contrast, liver-specific POR knockout mice created by cre/lox technology were grossly normal-developing, growing, and living as long as normal mice, and having normal reproductive capacity, indicating normal gonadal P450 function (312,313).”
From The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders (2011) · cites this paper as [312]
In the citing paper
“Furthermore these animals had dramatically decreased capacities to metabolize acetaminophen, phenobarbital, and testosterone despite having a 5-fold increase in total hepatic P450 content.”
From The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders (2011) · cites this paper as [312]
In the citing paper
“Liver-specific knockout of POR in mice decreases the activities of hepatic drug-metabolizing enzymes (312, 313), thereby potentially rendering some drugs teratogenic.”
From The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders (2011) · cites this paper as [312]
Citations
Cites
PROTEIN MEASUREMENT WITH THE FOLIN PHENOL REAGENT
Lowry, O., Rosebrough, N., Farr, A. L., & Randall, R. (1951) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)52451-6 · Cited by 317,331
Brown, M. S., & Goldstein, J. L. (1997) · Cell · doi:10.1016/s0092-8674(00)80213-5 · Cited by 3,834
P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature
Nelson, D. R., Koymans, L., Kamataki, T., Stegeman, J. J., Feyereisen, R., Waxman, D. J., Waterman, M. R., Gotoh, O., Coon, M. J., Estabrook, R. W., et al. (1996) · Pharmacogenetics · doi:10.1097/00008571-199602000-00002 · Cited by 2,945
Conney, A. H. (1982) · PubMed · Cited by 1,557
Postic, C., Shiota, M., Niswender, K. D., Jetton, T. L., Chen, Y., Moates, J. M., Shelton, K. D., Lindner, J., Cherrington, A. D., & Magnuson, M. A. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.1.305 · Cited by 1,302
Self-citationHayhurst, G. P., Lee, Y.-H., Lambert, G., Ward, J. M., & Gonzalez, F. J. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.4.1393-1403.2001 · Cited by 1,107
Shimano, H., Horton, J. D., Hammer, R. E., Shimomura, I., Brown, M. S., & Goldstein, J. L. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118951 · Cited by 816
The Role of Orphan Nuclear Receptors in the Regulation of Cholesterol Homeostasis
Repa, J. J., & Mangelsdorf, D. J. (2000) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.16.1.459 · Cited by 759
Role of CYP2E1 in the Hepatotoxicity of Acetaminophen
Lee, S. S. T., Buters, J. T. M., Pineau, T., Fernandez-Salguero, P., & Gonzalez, F. J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.20.12063 · Cited by 656
Sterol synthesis in vivo in 18 tissues of the squirrel monkey, guinea pig, rabbit, hamster, and rat
Spady, D. K., & Dietschy, J. M. (1983) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)37999-2 · Cited by 411
Research works printed but not linked: 4
- Pikuleva, 1999, Mol. Aspects Med., 20, 33
- Henderson, 1992, 10, 221
- Hines, 2001, Drug Metab. Dispos., 29, 623
- Conney, 1982, Cancer Res., 42, 4875
Cited by
The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders
Miller, W. L., & Auchus, R. J. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0013 · Cited by 2,458
The Human Obesity Gene Map: The 2005 Update
Rankinen, T., Zuberi, A., Chagnon, Y. C., Weisnagel, S. J., Argyropoulos, G., Walts, B., Pérusse, L., & Bouchard, C. (2006) · Obesity · doi:10.1038/oby.2006.71 · Cited by 1,119
“2 POR P450 (cytochrome) oxidoreductase Conditional KO (liver specific) Increased liver weight and fatty liver (506,507)”
BackgroundCytochrome P450s and other enzymes in drug metabolism and toxicity
Guengerich, F. P. (2006) · The AAPS Journal · doi:10.1208/aapsj080112 · Cited by 624
Oxidative Damage and Antioxidant Defense in Ferroptosis
Kuang, F., Liu, J., Tang, D., & Kang, R. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.586578 · Cited by 531
“Given that the conditional knockout of POR in the liver leads to a decrease in the metabolism and lipid accumulation in mice (Henderson et al., 2003), the pathological role of POR-mediated ferroptosis in tissue damage and metabolism disease is worthy of further study.”
BackgroundGachon, F., Olela, F. F., Schaad, O., Descombes, P., & Schibler, U. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.04.015 · Cited by 512
“For example, a similar phenotype has been observed in mice with a liver-specific disruption of the Por gene (Gu et al., 2003; Henderson et al., 2003 ).”
BackgroundHuang, N., Pandey, A. V., Agrawal, V., Reardon, W., Lapunzina, P. D., Mowat, D., Jabs, E. W., Vliet, G. V., Sack, J., Flück, C. E., et al. (2005) · The American Journal of Human Genetics · doi:10.1086/429417 · Cited by 336
“However, liver-specific knockout of Por yields morphologically normal mice (Henderson et al. 2003; Wu et al. 2003), whereas the global Por-knockout mouse is embryonic lethal (Shen et al.”
BackgroundMinireview: Regulation of Steroidogenesis by Electron Transfer
Miller, W. L. (2005) · Endocrinology · doi:10.1210/en.2005-0096 · Cited by 324
Preclinical experimental models of drug metabolism and disposition in drug discovery and development
Zhang, D., Luo, G., Ding, X., & Lu, C. (2012) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2012.10.004 · Cited by 309
NADPH P450 oxidoreductase: Structure, function, and pathology of diseases
Pandey, A. V., & Flück, C. E. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.01.010 · Cited by 279
LC-MS-Based Metabolomics in Drug Metabolism
Chen, C., Gonzalez, F. J., & Idle, J. R. (2007) · Drug Metabolism Reviews · doi:10.1080/03602530701497804 · Cited by 260
“…all P450 activities abolished by conditional knockout of aDetails of this study will be reported in a separate manuscript. cytochrome P450 reductase has been established, which can be used to determine whether P450s have any role in the metabolism of individual xenobiotic (Henderson et al., 2003).”
BackgroundInhibition of Cytochrome P450 Enzymes
Correia, M. A., & Hollenberg, P. F. (2015) · Cytochrome P450 · doi:10.1007/978-3-319-12108-6_5 · Cited by 257
Intestinal Microbiota Regulate Xenobiotic Metabolism in the Liver
Björkholm, B., Bok, C. M., Lundin, A., Rafter, J., Hibberd, M. L., & Pettersson, S. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006958 · Cited by 249
“Our observed association between lower expression of POR and the three PAR bZip genes; Dbp, Tef and Hlf, and the higher liver/body weight ratio in SPF are consistent with results from hepatic POR null mice [27] and PAR bZip triple knockouts [23] where the liver/body weight ratios are increased, most likely because of…”
ResultTakayama, K., Inamura, M., Kawabata, K., Katayama, K., Higuchi, M., Tashiro, K., Nonaka, A., Sakurai, F., Hayakawa, T., Kusuda Furue, M., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2011.234 · Cited by 235
Liver-specific Deletion of the NADPH-Cytochrome P450 Reductase Gene
Gu, J., Weng, Y., Zhang, Q.-Y., Cui, H., Behr, M., Wu, L., Yang, W., Zhang, L., & Ding, X. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303125200 · Cited by 214
Huang, N., Agrawal, V., Giacomini, K. M., & Miller, W. L. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711621105 · Cited by 198
“By contrast, liver-specific POR knockout mice are morphologically normal, reproductively competent and have normal life spans, but their hepatic drug metabolism is severely impaired (11).”
BackgroundLorbek, G., Lewinska, M., & Rozman, D. (2012) · The FEBS Journal · doi:10.1111/j.1742-4658.2011.08432.x · Cited by 196
Otto, D. M. E., Henderson, C. J., Carrie, D., Davey, M., Gundersen, T. E., Blomhoff, R., Adams, R. H., Tickle, C., & Wolf, C. R. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.17.6103-6116.2003 · Cited by 189
“However, conditional deletion of Cpr, specifically in the liver, the major organ for cytochrome P450 activity in an adult animal, although significantly interfering with hepatic metabolism, does not affect murine survival (12).”
BackgroundMethodSelf-citationVariation in CYP2A6 Activity and Personalized Medicine
Tanner, J.-A., & Tyndale, R. (2017) · Journal of Personalized Medicine · doi:10.3390/jpm7040018 · Cited by 172
“The fundamental role of POR in CYP enzyme function is illustrated by the substantial decrease in CYP activity in hepatic POR-deficient mice [82,83].”
BackgroundNADPH–Cytochrome P450 Oxidoreductase: Roles in Physiology, Pharmacology, and Toxicology
Riddick, D. S., Ding, X., Wolf, C. R., Porter, T. D., Pandey, A. V., Zhang, Q., Gu, J., Finn, R. D., Ronseaux, S., McLaughlin, L. A., et al. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.112.048991 · Cited by 164
“Department of Health, Albany, NY) independently published their studies on the conditional deletion of POR expression in mouse liver (Gu et al., 2003; Henderson et al., 2003).”
BackgroundSelf-citationSteroid hormone biotransformation and xenobiotic induction of hepatic steroid metabolizing enzymes
You, L. (2004) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2004.01.006 · Cited by 145
Arlt, V. M., Stiborová, M., Henderson, C. J., Thiemann, M., Frei, E., Aimová, D., Singh, R., da Costa, G. G., Schmitz, O. J., Farmer, P. B., et al. (2007) · Carcinogenesis · doi:10.1093/carcin/bgn002 · Cited by 143
Self-citationPass, G. J., Carrie, D., Boylan, M., Lorimore, S. A., Wright, E. G., Houston, B., Henderson, C. J., & Wolf, C. R. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4103 · Cited by 142
“Analysis of hepatic POR expression in the HRN mice used in these studies showed a profound reduction in POR levels and activity related to wild-type animals in that almost all hepatocytes were devoid of detectable POR expression (Fig.”
BackgroundMethodInfluentialSelf-citationGao, J., & Xie, W. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.035568 · Cited by 146
“Mouse models with liver-specific deletion of CPR were generated by two independent groups (Gu et al., 2003; Henderson et al., 2003).”
Function of human cytochrome P450s: Characterization of the orphans
Guengerich, F. P., Wu, Z., & Bartleson, C. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.08.079 · Cited by 133
“ablation of NADPH-P450 reductase in mouse liver in conditional knock-out animals, which effectively eliminates the function of all hepatic P450s, appears to have only a very limited physiological effect beyond the accumulation of cholesterol [11,12].”
BackgroundLycett, G. J., McLaughlin, L. A., Ranson, H., Hemingway, J., Kafatos, F. C., Loukeris, T. G., & Paine, M. J. I. (2006) · Insect Molecular Biology · doi:10.1111/j.1365-2583.2006.00647.x · Cited by 125
“However, this observation is reminiscent of liver-specific CPR knockout in adult mice, which remain viable despite lack of liver P450 function (Henderson et al ., 2003).”
BackgroundArlt, V. M., Stiborová, M., Henderson, C. J., Osborne, M. R., Bieler, C. A., Frei, E., Martínek, V., Sopko, B., Wolf, C. R., Schmeiser, H. H., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3544 · Cited by 121
“To evaluate the importance of hepatic POR in the reductive activation of 3-NBA to DNA adducts in vivo compared with cytosolic reduction and conjugation, we treated hepatic PORnull mice (30) and wild-type littermates i.”
BackgroundMethodSelf-citationMetabolic activation of carcinogenic aristolochic acid, a risk factor for Balkan endemic nephropathy
Stiborová, M., Frei, E., Arlt, V. M., & Schmeiser, H. H. (2007) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2007.07.003 · Cited by 118
“Mice carrying a deletion in the hepatic NADPH:CYP reductase gene [93,94], and thus lacking NADPH:CYP reductase and NADPH:CYP reductase-mediated CYP activity in hepatocytes will be used.”
MethodAgrawal, V., Huang, N., & Miller, W. L. (2008) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32830054ac · Cited by 117
Genetic and clinical features of P450 oxidoreductase deficiency
Scott, R. R., & Miller, W. L. (2008) · Hormone Research in Paediatrics · doi:10.1159/000114857 · Cited by 115
Oneda, B., Crettol, S., Sirot, E. J., Bochud, M., Ansermot, N., & Eap, C. B. (2009) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32833225e7 · Cited by 115
Structural diversity of cytochrome P450 enzyme system
Omura, T. (2010) · The Journal of Biochemistry · doi:10.1093/jb/mvq001 · Cited by 112
Gu, J., Cui, H., Behr, M. J., Li, Z., Zhang, Q.-Y., Yang, W., Hinson, J., & Ding, X. (2004) · Molecular Pharmacology · doi:10.1124/mol.104.007898 · Cited by 114
“We and others (Gu et al., 2003; Henderson et al., 2003) have recently developed one such model (named the liver-specific Cpr-null mouse, and referred to as Null mouse in the present article), in which the gene encoding NADPH-cytochrome P450 reductase (Cpr), the obligate redox partner for all microsomal P450s, is delet…”
InfluentialAgrawal, V., Choi, J. H., Giacomini, K. M., & Miller, W. L. (2010) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32833e0cb5 · Cited by 104
Zhu, F., Sams, S., Moural, T. W., Haynes, K. F., Potter, M. F., & Palli, S. R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031037 · Cited by 115
“multiple developmental defects and embryonic lethality in mouse [47,48] and increase the permethrin susceptibility in An gambiae”
Human and animal hepatocytes in vitro with extrapolation in vivo
O'Brien, P. J., Chan, K., & Silber, P. M. (2004) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2004.09.003 · Cited by 114
Hart, S. N., Wang, S., Nakamoto, K., Wesselman, C., Li, Y., & Zhong, X.-B. (2008) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3282f2f121 · Cited by 98
Pharmacogenomics of human P450 oxidoreductase
Pandey, A. V., & Sproll, P. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00103 · Cited by 92
“The liver-specific knockout of POR produces mice with lower metabolism and lipid accumulation (Gu et al., 2003; Henderson et al., 2003; Porter et al., 2011).”
BackgroundQuercetin Induces Hepatic Lipid Omega-Oxidation and Lowers Serum Lipid Levels in Mice
den Hil, E. F. H.-V., Keijer, J., Bunschoten, A., Vervoort, J. J. M., Staňková, B., Bekkenkamp‐Grovenstein, M., Herreman, L., Venema, D. P., Hollman, P. C. H., TVRZICKÁ, E., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0051588 · Cited by 94
“Based on these observations, it was concluded that the P450 system plays a major role in regulating lipid homeostasis and hepatic lipid levels [33,34].”
BackgroundWeng, Y., Fang, C., Turesky, R. J., Behr, M. J., Kaminsky, L. S., & Ding, X. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1006 · Cited by 101
Finn, R. D., McLaughlin, L. A., Ronseaux, S., Rosewell, I. R., Houston, J. B., Henderson, C. J., & Wolf, C. R. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m803496200 · Cited by 95
Self-citationUnsaturated fatty acid regulation of cytochrome P450 expression via a CAR-dependent pathway
Finn, R. D., Henderson, C. J., Scott, C. L., & Wolf, C. R. (2008) · Biochemical Journal · doi:10.1042/bj20080740 · Cited by 98
Self-citationAlmira Correia, M., Sinclair, P. R., & De Matteis, F. (2011) · Drug Metabolism Reviews · doi:10.3109/03602532.2010.515222 · Cited by 88
Consequences of POR mutations and polymorphisms
Miller, W. L., Agrawal, V., Sandee, D., Tee, M. K., Huang, N., Choi, J. H., Morrissey, K., & Giacomini, K. M. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2010.10.022 · Cited by 88
“By contrast, liver-specific POR knockout mice were grossly normal, had a normal life span and had normal reproductive capacity, indicating normal gonadal P450 function (Gu et al., 2003; Henderson et al., 2003).”
BackgroundReed, L., Arlt, V. M., & Phillips, D. H. (2018) · Carcinogenesis · doi:10.1093/carcin/bgy058 · Cited by 100
“However, hepatic cytochrome P450 reductase null (HRN) mice, in which POR is deleted specifically in hepatocytes, are viable and exhibit no overt phenotypical differences from wild-type mice other than having steatotic livers as a consequence of non-functioning P450-housekeeping activity involved in cholesterol metabol…”
BackgroundDostálek, M., Hardy, K. D., Milne, G. L., Morrow, J. D., Chen, C., Gonzalez, F. J., Gu, J., Ding, X., Johnson, D. A., Johnson, J. A., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m802447200 · Cited by 89
Deletion of Microsomal Cytochrome b5 Profoundly Affects Hepatic and Extrahepatic Drug Metabolism
McLaughlin, L. A., Ronseaux, S., Finn, R. D., Henderson, C. J., & Wolf, C. R. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.064246 · Cited by 81
“A similar increase in P450 expression was also observed when hepatic POR was conditionally deleted (Gu et al., 2003; Henderson et al., 2003), which in this latter case seems to be due to activation of the constitutive androstane receptor and, to a lesser degree, the pregnane X receptor by accumulated polyunsaturated f…”
BackgroundMethodSelf-citationTomalik-Scharte, D., Maiter, D., Kirchheiner, J., Ivison, H. E., Fuhr, U., & Arlt, W. (2010) · European Journal of Endocrinology · doi:10.1530/eje-10-0764 · Cited by 77
Hepatic cytochrome P450s metabolize aristolochic acid and reduce its kidney toxicity
Xiao, Y., Ge, M., Xue, X., Wang, C., Wang, H., Wu, X., Li, L., Liu, L., Qi, X., Zhang, Y., et al. (2008) · Kidney International · doi:10.1038/ki.2008.103 · Cited by 77
The Evolving Role of Drug Metabolism in Drug Discovery and Development
Yengi, L. G., Leung, L. Y., & Kao, J. (2007) · Pharmaceutical Research · doi:10.1007/s11095-006-9217-9 · Cited by 86
“However, the in vivo relevance of such data has not been established, hence can only be used as diagnostic rather than predictive tools (105,108,112).”
BackgroundMiller, W. L. (2004) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2004.07.005 · Cited by 82
Effects of genetic variants of human P450 oxidoreductase on catalysis by CYP2D6 in vitro
Sandee, D., Morrissey, K., Agrawal, V., Tam, H. K., Kramer, M. A., Tracy, T. S., Giacomini, K. M., & Miller, W. L. (2010) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32833f4f9b · Cited by 74
Electron Transfer Partners of Cytochrome P450
Paine, M. J. I., Scrutton, N. S., Munro, A. W., Gutiérrez, A., Roberts, G. C. K., & Wolf, C. R. (2007) · Springer eBooks · doi:10.1007/0-387-27447-2_4 · Cited by 79
Self-citationShi, L., Zhang, J., Shen, G., Xu, Z., Peng, W., Zhang, Y., Xu, Q., & He, L. (2015) · Scientific Reports · doi:10.1038/srep15581 · Cited by 77
Wu, L., Gu, J., Cui, H., Zhang, Q.-Y., Behr, M. J., Fang, C., Weng, Y., Kluetzman, K., Swiatek, P. J., Yang, W., et al. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.073353 · Cited by 71
“The in vivo function of hepatic CPR in adult mice has also been examined in liver-specific Cpr-null (liver-Cpr-null or Alb-Cre/Cprlox) mouse models (Gu et al., 2003; Henderson et al., 2003).”
BackgroundResultInfluentialConditional knockout of the mouse NADPH‐cytochrome p450 reductase gene
Wu, L., Gu, J., Weng, Y., Kluetzman, K., Swiatek, P., Behr, M., Zhang, Q., Zhuo, X., Xie, Q., & Ding, X. (2003) · genesis · doi:10.1002/gene.10214 · Cited by 68
“One of these studies (Gu et al., 2003) used the Cprlox model described here, whereas the other (Henderson et al., 2003) used a model in which the conditional Cpr allele had a loxP-neo-loxP cassette in intron 4 and an additional loxP site in intron 15.”
BackgroundMethodKnockout of hepatic P450 reductase aggravates triptolide-induced toxicity
Xue, X., Gong, L., Qi, X., Wu, Y., Xing, G., Yao, J., Luan, Y., Xiao, Y., Li, Y., Wu, X., et al. (2011) · Toxicology Letters · doi:10.1016/j.toxlet.2011.05.003 · Cited by 68
Weng, Y., Dirusso, C., Reilly, A. A., Black, P. N., & Ding, X. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m504447200 · Cited by 73
Inhibition of Cytochrome P450 Enzymes
Correia, M. A., & de Montellano, P. R. O. (2007) · Springer eBooks · doi:10.1007/0-387-27447-2_7 · Cited by 72
Proteomic analysis of the cold stress response in the moss, Physcomitrella patens
Wang, X., Yang, P., Zhang, X., Xu, Y., Kuang, T., Shen, S., & He, Y. (2009) · PROTEOMICS · doi:10.1002/pmic.200900062 · Cited by 69
“In plants, oxylipins have diverse functions, with prominence in responses to herbivory and pathogen invasion [52, 53].”
BackgroundHodek, P., Koblihová, J., Kizek, R., Frei, E., Arlt, V. M., & Stiborová, M. (2013) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2013.09.004 · Cited by 67
The Hepatic Circadian Clock Modulates Xenobiotic Metabolism in Mice
DeBruyne, J. P., Weaver, D. R., & Dallmann, R. (2014) · Journal of Biological Rhythms · doi:10.1177/0748730414544740 · Cited by 63
“Both PB and APAP have time-of-day dependent effects (Scheving et al., 1968; Sato et al., 2005; Xu et al., 2012; Kim and Lee, 1998; Kakan et al., 2011) and are metabolized exclusively by the cytochrome P450 (CYP) system of the liver (Henderson et al., 2006; Henderson et al., 2003).”
BackgroundInfluentialP450 oxidoreductase: genetic polymorphisms and implications for drug metabolism and toxicity
Hart, S. N., & Zhong, X.-B. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.4.4.439 · Cited by 70
“Interestingly, hepatocyte-specific POR knockout mice demonstrate a compensatory fivefold increase in total CYP content, indicating a negative feedback pathway regulating CYP gene expression [49] .”
BackgroundElectron Transfer Partners of Cytochrome P450
Waskell, L. A., & Kim, J. P. (2015) · Springer eBooks · doi:10.1007/978-3-319-12108-6_2 · Cited by 87
Wang, X. J., CHAMBERLAIN, M., Vassieva, O., Henderson, C. J., & Wolf, C. R. (2005) · Biochemical Journal · doi:10.1042/bj20042087 · Cited by 65
Self-citationSchmidt, K., Hughes, C., Chudek, J. A., Goodyear, S. R., Aspden, R. M., Talbot, R., Gundersen, T. E., Blomhoff, R., Henderson, C., Wolf, C. R., et al. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.01638-08 · Cited by 61
Self-citationHenderson, C. J., McLaughlin, L. A., & Wolf, C. R. (2013) · Molecular Pharmacology · doi:10.1124/mol.112.084616 · Cited by 60
Self-citationWoillard, J., Mourad, M., Neely, M. N., Capron, A., van Schaik, R. H., van Gelder, T., Lloberas, N., Hesselink, D. A., Marquet, P., Haufroid, V., et al. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00358 · Cited by 65
“Liver-specific POR-knockout mice are phenotypically normal but accumulate lipids in the liver and show considerably decreased hepatic drug metabolism (Henderson et al., 2003).”
BackgroundP450-Humanized and Human Liver Chimeric Mouse Models for Studying Xenobiotic Metabolism and Toxicity
Bissig, K., Han, W., Barzi, M., Kovalchuk, N., Ding, L., Fan, X., Pankowicz, F. P., Zhang, Q.-Y., & Ding, X. (2018) · Drug Metabolism and Disposition · doi:10.1124/dmd.118.083303 · Cited by 61
Kapelyukh, Y., Henderson, C. J., Scheer, N., Rode, A., & Wolf, C. R. (2019) · Drug Metabolism and Disposition · doi:10.1124/dmd.119.087718 · Cited by 60
“A separate experimental group consisted of mice with conditionally deleted hepatic P450 oxidoreductase (Henderson et al., 2003) [hepatic reductase null (HRN) mice].”
MethodSelf-citationFang, C., Behr, M. J., Xie, F., Lu, S., Doret, M., Luo, H., Yang, W., Aldous, K. M., Ding, X., & Gu, J. (2007) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2007.10.014 · Cited by 59
“With the availability of tissue-selective Cpr-null mouse models, such as the liver-Cprnull mice (Gu et al., 2003; Henderson et al., 2003) and the lung-Cpr-null mice (Weng et al., 2007), it is now possible to directly determine the in vivo contributions of the P450 enzymes in a given organ to the…”
MethodStanley, L. A. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802104-0.00027-5 · Cited by 66
Arlt, V. M., Henderson, C. J., Wolf, C. R., Schmeiser, H. H., Phillips, D. H., & Stiborová, M. (2005) · Cancer Letters · doi:10.1016/j.canlet.2005.03.035 · Cited by 58
Self-citationP450 oxidoreductase deficiency: a new form of congenital adrenal hyperplasia
Flück, C. E., & Miller, W. L. (2006) · Current Opinion in Pediatrics · doi:10.1097/01.mop.0000236395.71956.5c · Cited by 57
Drinking of Salvia officinalis tea increases CCl4-induced hepatotoxicity in mice
Lima, C. F., Fernandes‐Ferreira, M., & Pereira‐Wilson, C. (2006) · Food and Chemical Toxicology · doi:10.1016/j.fct.2006.09.009 · Cited by 57
Bardowell, S. A., Ding, X., & Parker, R. S. (2012) · Journal of Lipid Research · doi:10.1194/jlr.m030734 · Cited by 57
Liu, S., Liang, Q., Zhou, W., Jiang, Y.-D., Zhu, Q.-Z., Yu, H., Zhang, C., Gurr, G. M., & Zhu, Z. (2014) · Pest Management Science · doi:10.1002/ps.3760 · Cited by 60
Flück, C. E., Nicolo, C., & Pandey, A. V. (2007) · Fundamental & Clinical Pharmacology · doi:10.1111/j.1472-8206.2007.00520.x · Cited by 55
Genetic variation in human P450 oxidoreductase
Miller, W. L., Huang, N., Agrawal, V., & Giacomini, K. M. (2009) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.09.017 · Cited by 54
Levová, K., Moserová, M., Černá, V., Šulc, M., Henderson, C. J., Wolf, C. R., Phillips, D. H., Frei, E., Schmeiser, H. H., Mareš, J., et al. (2011) · Toxicological Sciences · doi:10.1093/toxsci/kfr050 · Cited by 54
“HRN (Porlox/lox + CreALB) mice on a C57BL/6 background (CXR Bioscience Ltd, Dundee, UK) used in this study were derived as described previously (Henderson et al., 2003a).”
InfluentialSelf-citationAutoantibodies Against CYP2D6 and Other Drug-Metabolizing Enzymes in Autoimmune Hepatitis Type 2
Mizutani, T., Shinoda, M., Tanaka, Y., Kuno, T., Hattori, A., Usui, T., Kuno, N., & Osaka, T. (2005) · Drug Metabolism Reviews · doi:10.1081/dmr-200028798 · Cited by 53
“Autoantibodies Against CYP Reductase and Transporters CYP is regenerated in a catalytic cycle of the MFO system by CP reductase (Guengerich 2001, Henderson et al., 2003).”
MethodThe Adrenal Cortex and its Disorders
Miller, W. L. (2009) · Brook's Clinical Pediatric Endocrinology · doi:10.1002/9781444316728.ch13 · Cited by 50
Zhang, Q., Fang, C., Zhang, J., Dunbar, D. A., Kaminsky, L. S., & Ding, X. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.025429 · Cited by 50
““hepatic P450 reductase null” mouse (Henderson et al., 2003), the”
BackgroundKwon, D., Kim, S., & Correia, M. A. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.11.002 · Cited by 54
Wang, Y., Liao, M., Hoe, N., Acharya, P., Deng, C., Krutchinsky, A. N., & Correia, M. A. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m806104200 · Cited by 53
Emmerstorfer‐Augustin, A., Wimmer‐Teubenbacher, M., Wriessnegger, T., Leitner, E., Müller, M., Kaluzna, I. A., Schürmann, M., Mink, D., Zellnig, G., Schwab, H., et al. (2015) · Biotechnology Journal · doi:10.1002/biot.201400780 · Cited by 50
Elmore, C. L., & Porter, T. D. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m210173200 · Cited by 53
Stiborová, M., Moserová, M., Černá, V., Indra, R., Dračínský, M., Šulc, M., Henderson, C. J., Wolf, C. R., Schmeiser, H. H., Phillips, D. H., et al. (2014) · Toxicology · doi:10.1016/j.tox.2014.02.002 · Cited by 49
Self-citationZhang, X., Li, L., Ding, X., & Kaminsky, L. S. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.038836 · Cited by 51
“…in patients is supported by several lines of data, including the impact of Por gene knockout on drug clearance in mouse models (Gu et al., 2003; Henderson et al., 2003; Zhang et al., 2009), positive correlations between POR activity and P450-mediated drug metabolism activities in human liver…”
ResultChen, X., Pan, L. Q., Naranmandura, H., Zeng, S., & Chen, S. Q. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038495 · Cited by 53
Influence of small doses of various drug vehicles on acetaminophen-induced liver injury
Kelava, T., Ćavar, I., & Čulo, F. (2010) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y10-065 · Cited by 46
“The sleeping time was defined as the sleep-time period from the loss of the righting reflex to its complete recovery (Piel et al. 1969; Henderson et al. 2003; Chan et al. 2009).”
BackgroundHenderson, C. J., Kapelyukh, Y., Scheer, N., Rode, A., McLaren, A. W., MacLeod, A. K., Lin, D., Wright, J., Stanley, L. A., & Wolf, C. R. (2019) · Drug Metabolism and Disposition · doi:10.1124/dmd.119.086397 · Cited by 44
“S-acenocoumarol metabolism inmicrosomes fromwild-type, Cyp2cKO, Cyp2c/2d/3a KO, or hepatic P450 reductase–null (Henderson et al., 2003) mice was practically indistinguishable from that in the no cofactor control, whereas S-acenocoumarol was rapidly metabolized in liver microsomes from CYP2C9 humanized mice (Fig.”
BackgroundSelf-citationTransgenic mice and metabolomics for study of hepatic xenobiotic metabolism and toxicity
Gonzalez, F. J., Fang, Z., & Ma, X. (2015) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2015.1032245 · Cited by 45
“For example, mice with a knockout of the hepatic CYP reductase gene, required for the catalytic activity of CYPs, are viable [26,27], thus indicating that CYPs involved in xenobiotic metabolism are not critical for reproduction and physiological homeostasis with minor alterations in liver function.”
BackgroundStiborová, M., Arlt, V. M., Henderson, C. J., Wolf, C. R., Černá, V., Moserová, M., Hudeček, J., Phillips, D. H., & Frei, E. (2007) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2007.09.017 · Cited by 43
Self-citationA novel humanized mouse lacking murine P450 oxidoreductase for studying human drug metabolism
Barzi, M., Pankowicz, F. P., Zorman, B., Liu, X., Legras, X., Yang, D., Borowiak, M., Bissig-Choisat, B., Sumazin, P., Li, F., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00049-x · Cited by 42
Elens, L., Nieuweboer, A. J. M., Clarke, S. J., Charles, K. A., de Graan, A. M., Haufroid, V., van Gelder, T., Mathijssen, R. H. J., & van Schaik, R. H. N. (2013) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32835dc113 · Cited by 46
Yang, G., Fu, Z.-M., Chen, X., Yuan, H., Yang, H., Huang, Y., Ouyang, D., Tan, Z.-R., Tan, H., Huang, Z., et al. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.11.004 · Cited by 45
Ismail, H. M., O’Neill, P. M., Hong, D. W., Finn, R. D., Henderson, C. J., Wright, A., Cravatt, B. F., Hemingway, J., & Paine, M. J. I. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320185110 · Cited by 44
“E. coli membranes coexpressing CYP6M2 or CYP6Z2 with CPR were prepared as previously described (11, 15).”
MethodSelf-citationHepatic cytochrome P450s play a major role in monocrotaline-induced renal toxicity in mice
Yao, J., Li, C., Gong, L., Feng, C., Li, C.-Z., Gao, M., Luan, Y., Qi, X., & Ren, J. (2013) · Acta Pharmacologica Sinica · doi:10.1038/aps.2013.145 · Cited by 40
Adrenodoxin supports reactions catalyzed by microsomal steroidogenic cytochrome P450s
Pechurskaya, T. A., Harnastai, I. N., Grabovec, I. P., Gilep, A. A., & Usanov, S. A. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.12.047 · Cited by 42
Role of Small Intestinal Cytochromes P450 in the Bioavailability of Oral Nifedipine
Zhang, Q.-Y., Kaminsky, L. S., Dunbar, D. A., Zhang, J., & Ding, X. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.016543 · Cited by 40
“Several mouse models targeting the Cpr locus have been developed, including the “Cpr-low” (CL) mouse (Wu et al., 2005), the “liver-Cpr-null” (LCN) mouse (Gu et al., 2003; Henderson et al., 2003), and the “Cpr-low and liver-Cpr-null” (CL-LCN) mouse (Gu et al., 2007).”
Metadata
- Authors
- Henderson, C. J., Otto, D. M. E., Carrie, D., Magnuson, M. A., McLaren, A. W., Rosewell, I., & Wolf, C. R.
- Affiliations
- Cancer Research UK (GB)
- Corresponding author
- Rosewell, Ian
- Wolf, C. Roland
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2003-04
- Volume
- 278
- Issue
- 15
- Pages
- 13480-13486
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2047821701
- Semantic Scholar
- 23689d9cea73d2a1ad2d52b9778fe58ba7110680
- Cited by
- 258
- References
- 52
- Citations by year
- 2026: 1 · 2025: 7 · 2024: 3 · 2023: 4 · 2022: 4 · 2021: 3 · 2020: 6 · 2019: 6 · 2018: 7 · 2017: 6 · 2016: 10 · 2015: 15 · 2014: 19 · 2013: 19 · 2012: 25
- FWCI
- 10.56
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 6409 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Discovery Research Portal (University of Dundee) (submittedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- NADPH-cytochrome P450 reductase, conditional gene deletion, bile acid synthesis, cholesterol metabolism, acetaminophen metabolism, steroid hormone metabolism
- MeSH terms
- Acetaminophen, Animals, Cytochrome P-450 Enzyme System, Exons, Female, Glutathione, Liver, Male, Mice, Transgenic, NADPH-Ferrihemoprotein Reductase, Pentobarbital, Promoter Regions, Genetic, Serum Albumin, Sex Characteristics, Restriction Mapping, Genomic Library, Gene Deletion, Mice, Knockout, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.